Kaplan Fox & Kilsheimer LLP has issued an alert regarding a securities class action lawsuit filed against Zoetis Inc. (NYSE: ZTS) on behalf of investors who acquired the company's securities between January 14, 2025 and May 6, 2026. The complaint alleges that Zoetis misled investors by portraying its Companion Animal segment as a durable growth engine driven by expanding markets and strong veterinarian adoption, while allegedly concealing serious safety concerns, intensifying competition, and declining veterinarian confidence that were eroding sales growth and financial outlook. The lawsuit claims the full extent of these issues was revealed on May 7, 2026, when Zoetis reported first quarter 2026 financial results showing significant deterioration in its core Companion Animal business and sharply reduced full-year guidance. Following this announcement, Zoetis stock fell $23.91 per share, or 21.5%, to close at $87.31 per share on that date. The complaint asserts that throughout the class period, defendants knew or recklessly disregarded that veterinarian prescription growth for Librela was weakening due to FDA safety warnings regarding serious neurological complications in dogs, Simparica Trio was losing market share to a lower-priced competitor with broader indicated use, and dermatology products Apoquel and Cytopoint were losing substantial market share to a newly launched competing canine treatment. Investors who suffered losses during the class period are encouraged to contact Kaplan Fox via email at [email protected] or by calling (646) 315-9003 for more information about the lead plaintiff process. Members of the proposed class may move the court no later than July 27, 2026 to serve as a lead plaintiff, though participation in that role is not required to share in any possible recovery. The firm notes that contacting them does not create an attorney-client relationship or an obligation to retain the client, and this press release may be considered attorney advertising in some jurisdictions.